Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...
Stock analysts at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of Anavex Life Sciences in ...
H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...
H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Biotricity (BTCY – Research Report) today. The company’s shares closed yesterday ...
H.C. Wainwright analyst Patrick Trucchio revised the price target on Compass Pathways (NASDAQ:CMPS) stock, reducing it to $45 ...
On Tuesday, H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics Inc (NASDAQ:TNYA), with a price target of $18.00. This aligns with the strong overall analyst ...
Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (BRSE:1CG) with a Buy recommendation. There are 575 funds or institutions reporting positions ...
On January 31, the company announced that H.C. Wainwright & Co. has initiated coverage on it with a “Buy” rating and a 12-month price target of $16 per share. The report highlights several ...
--(BUSINESS WIRE)--Knightscope, Inc. (NASDAQ: KSCP), an innovator in robotics and artificial intelligence technologies focused on public safety, today announced that H.C. Wainwright & Co. has ...